Phase III Studies of MuDelta Introduced by Furiex

Furiex Pharmaceuticals, Inc. introduced dosing of this very first affected person in the Phase III randomized, double-blind, placebo-controlled research studies evaluating performance, overall safety and tolerability of MuDelta within the remedy for diarrhea-predominant irritable bowel syndrome (IBS-D). Furiex is enacting two subsequent Phase III trials, one with a 52-week therapy time frame and maybe with a 30-week treatment period, in study centers in the USA, Canada and United Kingdom. Combined, the trials are required to enroll about 2,250 affected individuals.

Furiex formerly introduced the effective completion and end result of its Phase II study to determine the safety and performance associated with the oral formulation of MuDelta in affected individuals with IBS-D. The research achieved statistically and clinically large results for its primary in addition to a number of key secondary endpoints, and demonstrated long lasting efficacy throughout the 12-week therapy period.

"MuDelta is a first-in-class compound, then we are extremely satisfied that this Phase III trials have commenced trying to find forward to further advancing the expansion plan for this vital therapeutic applicant," said June Almenoff, M.D., Ph.D., president and chief medicinal official of Furiex.